{"title":"Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours","authors":"Diana Romero","doi":"10.1038/s41571-025-01005-1","DOIUrl":null,"url":null,"abstract":"<p>Chimeric proteins resulting from fusions involving <i>NRG1</i>, which encodes a growth factor from the EGF family, promote HER2–HER3 heterodimerization and subsequent oncogenic activation of cell proliferation. These fusions occur in <1% of solid tumours including non-small-cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PDAC). Now, data from the phase II eNRGy trial demonstrate that the HER2 × HER3 bispecific antibody zenocutuzumab is efficacious and safe in patients with advanced-stage <i>NRG1</i> fusion-positive solid tumours.</p><p>The primary efficacy population comprised 158 patients with one of ten solid tumour types, primarily NSCLC (<i>n</i> = 94) and PDAC (<i>n</i> = 36). Most patients had received previous systemic therapy for metastatic disease, including 77% and 92% of those with NSCLC and PDAC, respectively. The primary end point was objective response rate (ORR).</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"2 1","pages":""},"PeriodicalIF":82.2000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01005-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Chimeric proteins resulting from fusions involving NRG1, which encodes a growth factor from the EGF family, promote HER2–HER3 heterodimerization and subsequent oncogenic activation of cell proliferation. These fusions occur in <1% of solid tumours including non-small-cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PDAC). Now, data from the phase II eNRGy trial demonstrate that the HER2 × HER3 bispecific antibody zenocutuzumab is efficacious and safe in patients with advanced-stage NRG1 fusion-positive solid tumours.
The primary efficacy population comprised 158 patients with one of ten solid tumour types, primarily NSCLC (n = 94) and PDAC (n = 36). Most patients had received previous systemic therapy for metastatic disease, including 77% and 92% of those with NSCLC and PDAC, respectively. The primary end point was objective response rate (ORR).
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
